Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action

NCT04271202 is registered in ClinicalTrials.gov with Beth Israel Deaconess Medical Center as lead sponsor.

NCT NCT04271202
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04271202 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action
Lead sponsor
Beth Israel Deaconess Medical Center
Phase
Phase 4
Overall status
Completed
Start date
July 29, 2020
Completion date
November 22, 2023
Enrollment
64 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic migraine